Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
Abstract Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real‐world data are limited. This real‐world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in a...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.595 |
| _version_ | 1797263316637188096 |
|---|---|
| author | Xavier Leleu Eirini Katodritou Thomas Kuehr Evangelos Terpos Jo Caers Renato Zambello Alessandra Brescianini Tony Liang Sally Wetten Sorina N. Badelita |
| author_facet | Xavier Leleu Eirini Katodritou Thomas Kuehr Evangelos Terpos Jo Caers Renato Zambello Alessandra Brescianini Tony Liang Sally Wetten Sorina N. Badelita |
| author_sort | Xavier Leleu |
| collection | DOAJ |
| description | Abstract Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real‐world data are limited. This real‐world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in adults with RRMM. Data are presented for a subset of patients (n = 383) who received carfilzomib in combination with lenalidomide and dexamethasone (KRd). The overall response rate (ORR) was 83.6% among 360 evaluable patients. Treatment responses were better when KRd was administered at earlier therapy lines than at later lines of therapy (ORR: second line, 85.3%; third line or later, 81.0%). In patients with the anti‐CD38 antibody‐refractory disease, ORR was higher when KRd was administered earlier than at later therapy lines (second line/third line, 75.0%; fourth line or later, 60.0%). An ORR of 68.1% and 82.0% was achieved in the lenalidomide‐refractory and not lenalidomide‐refractory subgroups, respectively. KRd was consistently administered per the European label (twice weekly dose of 27 mg/m2) and the median time to discontinuation was 14.6 months. The safety profile of KRd was consistent with previous studies. These real‐world data highlight the effectiveness of KRd as a treatment for patients with RRMM, including those with disease refractory to lenalidomide or anti‐CD38 antibodies. |
| first_indexed | 2024-03-12T14:06:30Z |
| format | Article |
| id | doaj.art-37cd25a7f41e48c4ad559bd240ebb922 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-04-25T00:11:04Z |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-37cd25a7f41e48c4ad559bd240ebb9222024-03-13T13:30:47ZengWileyeJHaem2688-61462023-02-014117418310.1002/jha2.595Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and IsraelXavier Leleu0Eirini Katodritou1Thomas Kuehr2Evangelos Terpos3Jo Caers4Renato Zambello5Alessandra Brescianini6Tony Liang7Sally Wetten8Sorina N. Badelita9Department of Haematology University Hospital Centre La Miletrie and Inserm Poitiers FranceDepartment of Haematology Theagenio Cancer Hospital Thessaloniki GreeceDepartment of Internal Medicine IV Academic Teaching Hospital Wels‐Grieskirchen Wels AustriaDepartment of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens Athens GreeceDepartment of Haematology Liège University Hospital Centre Liège BelgiumDepartment of Medicine Haematology and Clinical Immunology Branch, University of Padua Padua ItalyResearch and Development Department Amgen (Europe) GmbH Rotkreuz SwitzerlandDepartment of Biostatistics Parexel International Taipei TaiwanCenter for Observational Research Amgen Ltd Uxbridge UKDepartment of Hematology Fundeni Clinical Institute Bucharest RomaniaAbstract Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real‐world data are limited. This real‐world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in adults with RRMM. Data are presented for a subset of patients (n = 383) who received carfilzomib in combination with lenalidomide and dexamethasone (KRd). The overall response rate (ORR) was 83.6% among 360 evaluable patients. Treatment responses were better when KRd was administered at earlier therapy lines than at later lines of therapy (ORR: second line, 85.3%; third line or later, 81.0%). In patients with the anti‐CD38 antibody‐refractory disease, ORR was higher when KRd was administered earlier than at later therapy lines (second line/third line, 75.0%; fourth line or later, 60.0%). An ORR of 68.1% and 82.0% was achieved in the lenalidomide‐refractory and not lenalidomide‐refractory subgroups, respectively. KRd was consistently administered per the European label (twice weekly dose of 27 mg/m2) and the median time to discontinuation was 14.6 months. The safety profile of KRd was consistent with previous studies. These real‐world data highlight the effectiveness of KRd as a treatment for patients with RRMM, including those with disease refractory to lenalidomide or anti‐CD38 antibodies.https://doi.org/10.1002/jha2.595carfilzomibmultiple myelomaproteasome inhibitorreal worldrelapsed/refractory |
| spellingShingle | Xavier Leleu Eirini Katodritou Thomas Kuehr Evangelos Terpos Jo Caers Renato Zambello Alessandra Brescianini Tony Liang Sally Wetten Sorina N. Badelita Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel eJHaem carfilzomib multiple myeloma proteasome inhibitor real world relapsed/refractory |
| title | Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel |
| title_full | Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel |
| title_fullStr | Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel |
| title_full_unstemmed | Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel |
| title_short | Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel |
| title_sort | real world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in europe and israel |
| topic | carfilzomib multiple myeloma proteasome inhibitor real world relapsed/refractory |
| url | https://doi.org/10.1002/jha2.595 |
| work_keys_str_mv | AT xavierleleu realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT eirinikatodritou realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT thomaskuehr realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT evangelosterpos realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT jocaers realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT renatozambello realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT alessandrabrescianini realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT tonyliang realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT sallywetten realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael AT sorinanbadelita realworlduseofcarfilzomibcombinedwithlenalidomideanddexamethasoneinpatientswithmultiplemyelomaineuropeandisrael |